1. Scrip
  2. >>Business

AgomAb Raises €21m Series A To Regenerate Damaged Tissues

 
• By Mike Ward

Ghent, Belgium-based start-up, AgomAb Therapeutics NV secures funds and license to develop HGF-mimetic agonistic monoclonal antibodies for regeneration of damaged tissues.

Human antibody
AgomAb develops agonistic antibodies for regeneration of damaged tissues • Source: Shutterstock

Established in 2017, AgomAb Therapeutics has emerged from stealth mode with a €21m series A round, co-led by V-Bio Ventures and Advent France Biotechnology in a syndicate including Boehringer Ingelheim Venture Fund, Omnes and Pontifax. The funds will be used to develop agonistic antibodies and antigen-binding fragments that bind with high affinity to both the human and mouse hepatocyte growth factor (HGF) receptor, also known as MET, for regeneration of damaged tissues. Preclinical data suggest that the approach has application across a number of indications.

Contemporaneously, the Ghent-based company has unveiled an established leadership team that includes: founder and CSO Paolo Michieli, laboratory chief at the University of Torino Medical School; CEO Tim Knotnerus, formerly VP corporate development at AM-Pharma BV; Chief development officer Torsten Dreier, previously co-founder and chief development officer at

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

More from Scrip

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Roche Reveals Another US Manufacturing Site As Tariff Pressures Seem To Ease

 
• By Mandy Jackson

Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.